Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes.

Farxiga (dapagliflozin) and Jardiance (empagliflozin) are prescription medications that are commonly used for type 2 diabetes ...

Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has been approved for chronic kidney disease in the EU - the first major market to clear the new use for the drug. Adding CKD to the ...

The Jardiance jingle probably rings through your head for several hours after you watch the ad, and that's the point. You ...